



Insights Into Renal Cell Carcinoma (RCC)

March 27, 2026

Dallas, TX

This report is the proprietary property of Aptitude Health. It may not be uploaded to any AI system or used to train any AI system without Aptitude Health's prior written consent.

How to Navigate This Report



Click to move to topic
of interest or ARS
supporting data



Click to return to
previous slide

Report Contents



Quick Links

Report Snapshot



> Session overview



> Session agenda



> Attendee overview



Scope of the Report



Topline Takeaways



Detailed Insights and Strategic Recommendations



Attendee Key Takeaways



ARS Data





Report Snapshot

Report Snapshot: Session Overview



Disease state and data presentations were led on **March 27, 2026**, by **Qian Qin, MD**, from UT Southwestern, and moderated by **Sushil Bhardwaj, MD, FACP**, from Good Samaritan Hospital, with content developed in conjunction with the Aptitude Health scientific team



The objectives of the meeting were to gain insights on the following

- > **Factors that influence the adoption of first-line and subsequent therapies for advanced RCC and their impact on patient treatment in the community**
- > **Current attitudes toward recently introduced and upcoming combination therapies**



Data collection was accomplished through use of **audience response system (ARS)** questioning and **moderated discussion**



Insights on the management of advanced RCC were obtained from **11 community oncologists** from Texas, United States

Report Snapshot: Session Agenda



Time (CT)	Topic
2.00 PM – 2.15 PM (5-min overview; 10-min ARS)	Introduction > Program overview > ARS questions
2.15 PM – 3.35 PM (35-min presentation; 45-min discussion)	First-Line Therapy of Advanced RCC > Overview of current data > Reaction and discussion
3.35 PM – 3.45 PM (10 min)	BREAK
3.45 PM – 4.45 PM (5-min ARS questions; 20-min presentation; 35-min discussion)	Subsequent Management of Advanced RCC > ARS questions > Overview of current data > Reaction and discussion
4.45 PM – 5.00 PM (15 min)	Key Takeaways and Meeting Evaluation

Report Snapshot: Attendee Overview



Scope of the Report



Topline Takeaways



Topline Takeaways	
1. The majority of respondents (80%) believe that the current state of the world is a crisis.	1. The majority of respondents (80%) believe that the current state of the world is a crisis.
2. The majority of respondents (75%) believe that the current state of the world is a crisis.	2. The majority of respondents (75%) believe that the current state of the world is a crisis.
3. The majority of respondents (70%) believe that the current state of the world is a crisis.	3. The majority of respondents (70%) believe that the current state of the world is a crisis.



**Detailed Insights and
Strategic Recommendations**

Objective 1: Detailed Insights (1/2)



Objective 1: Detailed Insights (1/2)

Learning Objectives: After completing this objective, you should be able to:

- 1. Explain the importance of understanding the underlying reasons for a company's performance, including its financial, operational, and strategic performance.
- 2. Identify the key drivers of a company's performance, such as its revenue, costs, and assets.
- 3. Analyze the company's performance using various financial ratios and metrics.
- 4. Evaluate the company's performance using a variety of tools and techniques, including the DuPont analysis, the Economic Value Added (EVA) analysis, and the Balanced Scorecard.
- 5. Compare the company's performance to its peers and to industry benchmarks.
- 6. Identify the strengths and weaknesses of the company's performance.
- 7. Develop a plan to improve the company's performance.

Objective 1: Detailed Insights (2/2)

Table 1 *Continued*

© 2005 The Authors
Journal compilation © 2005 Blackwell Publishing Ltd

- **active** – generalizing decomposition using regular constraints: $AB \rightarrow AC$ requires all AB combinations appearing in AB to appear with AC (possibly $AC \rightarrow AB$)
- **representative** – requires chosen number distinct values with AB combinations along the regular $AC \rightarrow AB$ and $AB \rightarrow AC$ (all combinations do not appear combinations in the user data)
- **covered** – generalizing decomposition by number using values along $AB \rightarrow AC$ combinations with AB combinations along the regular $AC \rightarrow AB$ (possibly $AB \rightarrow AC$) and $AB \rightarrow AC$ (all regular AB appear in AB in the user data)
- $AB \rightarrow AC$ requires AB to appear when $AC \rightarrow AB$ is also needed eg. $AB \rightarrow AC$ is necessary in $AB \rightarrow AC$

© 2004 Blackwell Publishing Ltd, *Journal of Internal Medicine* 255: 103–110

- Strong evidence (based on the comparison of 95% confidence intervals) that no patient had been able to change 95% upper limit (11 patients) or no 95% change. [View details](#)

doi:10.1371/journal.pone.0142000.g001

Objective 1: Supportive Quotes From Discussion (1/2)



Supportive Quotes From Discussion (1/2)	
Quote	Response
Quote 1	Response 1
Quote 2	Response 2
Quote 3	Response 3
Quote 4	Response 4
Quote 5	Response 5

Objective 1: Supportive Quotes From Discussion (2/2)



Supportive Quotes From Discussion (2/2)	
Topic	Supportive Quotes
Topic 1: Supportive Quotes	Quote 1: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 2: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 3: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it."
Topic 2: Supportive Quotes	Quote 1: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 2: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 3: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 4: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 5: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 6: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 7: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it." Quote 8: "I think the most important thing is to make sure that the data is accurate and that the results are reliable. This is why it's important to have a good understanding of the data and to use the right tools to analyze it."

Objective 1: Strategic Recommendations



Strategic Recommendation 1: Enhance the patient experience by streamlining the care journey, from appointment scheduling to treatment delivery and follow-up.

- Implement a centralized patient portal that allows patients to schedule appointments, view test results, and communicate with their care team.
- Introduce a patient navigation role to assist patients in understanding their care journey and navigating the healthcare system.
- Implement a standardized patient journey map across all care settings to ensure a consistent and seamless experience.

Strategic Recommendation 2: Optimize the operational efficiency of the care delivery model.

- Implement a standardized care pathway for common conditions to ensure consistent and high-quality care.
- Introduce a centralized scheduling system to optimize resource utilization and reduce wait times.
- Implement a standardized data collection and reporting system to monitor and improve operational efficiency.

Strategic Recommendation 3: Strengthen the financial sustainability of the organization through revenue cycle management and cost reduction.

- Implement a centralized revenue cycle management system to optimize billing and collections.
- Introduce a centralized procurement system to optimize purchasing and reduce costs.
- Implement a standardized financial reporting system to monitor and improve financial performance.

Strategic Recommendation 4: Enhance the organizational culture and workforce to support the strategic vision.

- Implement a centralized training and development system to ensure all staff are equipped with the necessary skills and knowledge.
- Introduce a centralized performance management system to monitor and improve staff performance.
- Implement a standardized communication system to ensure all staff are aligned with the organization's mission and vision.

Objective 2: Detailed Insights (1/4)



Section 1: Introduction

The purpose of this document is to provide a detailed overview of the project's objectives and scope. It is intended for use by all stakeholders involved in the project, including the project manager, team members, and external partners.

Section 2: Objectives

The project has three main objectives:

- 1. To develop a comprehensive business plan for the new product line.
- 2. To conduct a thorough market analysis to identify potential risks and opportunities.
- 3. To establish a strong marketing strategy to ensure the successful launch of the product.

Section 3: Scope

The project scope is defined by the following parameters:

- 1. The project will focus on the development and launch of a new product line.
- 2. The project will cover the period from January 1st to December 31st of the current year.
- 3. The project will involve the participation of all relevant departments, including R&D, Marketing, and Sales.

Section 4: Conclusion

In conclusion, the project is a critical component of the company's long-term strategy. It is essential that all stakeholders remain committed to the project's goals and objectives throughout its duration.

Objective 2: Detailed Insights (2/4)

Notes: The above information is preliminary and subject to change without notice. It is not intended to constitute an offer or recommendation to buy or sell securities or other financial products. Please consult your broker or investment advisor for more information.

© 2000 Blackwell Science Ltd *Journal of Internal Medicine* 247: 399–406

- [illegible]

© 2004 Blackwell Publishing Ltd *Journal of Internal Medicine* 255: 103–110

- The agency is generally not responsible for the agency's conduct when it acts in its capacity as a private party.
- The agency is not responsible for the agency's conduct when it acts in its capacity as a private party.
- The agency is not responsible for the agency's conduct when it acts in its capacity as a private party.
- The agency is not responsible for the agency's conduct when it acts in its capacity as a private party.

- Source: *Journal of the American Statistical Association*, 1997, Vol. 92, No. 439, pp. 1092-1103. Reprinted by permission of the American Statistical Association.

Objective 2: Detailed Insights (3/4)

Section 1: Introduction to the Case Study

This section introduces the case study, providing background information and context. It outlines the objectives of the study and the scope of the analysis.

Section 2: Data Collection and Analysis

- 1. Data Collection: This section details the methods used to collect data, including surveys, interviews, and observations.
- 2. Data Analysis: This section describes the analytical techniques used to process the data, such as statistical analysis and thematic analysis.

Section 3: Findings and Discussion

- 1. Findings: This section presents the key findings of the study, organized into thematic areas.
- 2. Discussion: This section discusses the implications of the findings, comparing them to existing literature and theoretical frameworks.

Section 4: Conclusion and Recommendations

- 1. Conclusion: This section summarizes the main points of the study and the overall conclusions.
- 2. Recommendations: This section provides practical recommendations based on the findings, aimed at addressing the research objectives.

Objective 2: Detailed Insights (4/4)



Objective 2: Supportive Quotes From Discussion (1/7)



Supportive Quotes From Discussion (1/7)	
Topic	Supportive Quotes
Topic 1: [illegible]	[illegible] [illegible] [illegible] [illegible]
Topic 2: [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible]

Objective 2: Supportive Quotes From Discussion (2/7)



Topic	Supportive Quotes
Topic 1: [illegible]	[illegible] [illegible] [illegible]
Topic 2: [illegible]	[illegible] [illegible] [illegible] [illegible]

Objective 2: Supportive Quotes From Discussion (3/7)



Supportive Quotes From Discussion (3/7)	
Topic	Supportive Quotes
Topic 1: [Topic Name]	[Quote 1]
	[Quote 2]
	[Quote 3]
	[Quote 4]
	[Quote 5]
	[Quote 6]
	[Quote 7]
	[Quote 8]
Topic 2: [Topic Name]	[Quote 9]
	[Quote 10]
	[Quote 11]

Objective 2: Supportive Quotes From Discussion (4/7)



Supportive Quotes From Discussion (4/7)	
Quote	Response
Quote 1	Response 1
Quote 2	Response 2
Quote 3	Response 3
Quote 4	Response 4
Quote 5	Response 5
Quote 6	Response 6
Quote 7	Response 7
Quote 8	Response 8
Quote 9	Response 9
Quote 10	Response 10

Objective 2: Supportive Quotes From Discussion (5/7)

Type	Keynote Statement
Statement of Commitment	When you talk to the House, the Senate, the Judiciary, or any other branch of government, you are talking to the people. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world.
Statement of Commitment	When you talk to the House, the Senate, the Judiciary, or any other branch of government, you are talking to the people. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world. You are talking to the people who are the most important people in the world.

Objective 2: Supportive Quotes From Discussion (6/7)



Topic	Supportive Quotes
Topic 1: [Illegible]	[Illegible text block containing multiple paragraphs of supportive quotes]

Objective 2: Supportive Quotes From Discussion (7/7)



Supportive Quotes From Discussion (7/7)	
Topic	Supportive Quotes
Topic 1	Quote 1: "The first step in the process of change is to identify the problem and to understand the reasons why it is a problem. This is often the most difficult step, but it is essential if we are to make any progress at all." Quote 2: "The second step is to develop a plan of action. This should be based on a thorough understanding of the problem and the reasons why it is a problem. It should also be based on a realistic assessment of the resources available to us."
Topic 2	Quote 3: "The third step is to implement the plan. This is often the most difficult step, but it is essential if we are to make any progress at all. It requires a great deal of courage and determination, and it often involves facing a great deal of opposition." Quote 4: "The fourth step is to evaluate the results. This is often the most difficult step, but it is essential if we are to make any progress at all. It requires a great deal of honesty and self-criticism, and it often involves facing a great deal of criticism from others."

Objective 2: Strategic Recommendations

Abstract – This paper reports on a study of the use of support services by 100 students attending a large university. The study found that students use support services for a variety of reasons, including academic difficulties, personal problems, and social issues. The study also found that students who use support services are more likely to succeed in their studies than those who do not. The study has implications for the development of support services for students.

Results presented in column 4 of the bottom row of Table 10 show that the effect of the 1990s on the 1990s is positive and significant at the 1% level.

- Information for authors is the most broadly accessible 50- to 60-page, non-peer-reviewed booklet, which will assist in understanding the journal's requirements for submitting articles, with particular emphasis on such matters as the submission

© 2000 Blackwell Science Ltd *Journal of Internal Medicine* 247: 399–406

- Copyright 1999, American Society of Civil Engineers. All rights reserved. This manuscript is for personal use only; all rights are reserved. No part of this manuscript may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or by any information storage or retrieval system, without permission in writing from the American Society of Civil Engineers.

© 2004 Blackwell Publishing Ltd *Journal of Internal Medicine* 255: 105–112

- © 2000 Blackwell Science Ltd, *Journal of Internal Medicine* 247: 395–402

Help with our award-winning customer service is available 24/7 by calling 1-800-828-6882 or help@sonnet.com.

- Copyright © 2007 John Wiley & Sons, Inc. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as may be permitted in writing by John Wiley & Sons, Inc. This publication is intended solely for the personal use of the individual user and is not to be disseminated broadly. Reproduction or translation of this work by others is prohibited. This publication may be registered at the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923.

Objective 3: Detailed Insights (1/2)



Case Study: The Role of the Nurse in the Management of the Patient with a Mental Health Problem

Learning Objectives:

- Understand the role of the nurse in the management of the patient with a mental health problem.
- Identify the key components of the nurse's role in the management of the patient with a mental health problem.
- Understand the importance of the nurse's role in the management of the patient with a mental health problem.

Key Points:

- The nurse's role is to provide support and care to the patient with a mental health problem.
- The nurse's role is to help the patient to understand their condition and to manage their symptoms.
- The nurse's role is to help the patient to access the services they need.
- The nurse's role is to help the patient to live a better quality of life.

Conclusion:

The nurse's role is a vital part of the management of the patient with a mental health problem. The nurse's role is to provide support and care to the patient, to help the patient to understand their condition, and to help the patient to access the services they need. The nurse's role is to help the patient to live a better quality of life.

Objective 3: Detailed Insights (2/2)



Figure 3: Detailed Insights (2/2)

The following table provides a detailed breakdown of the data presented in the previous figure, categorized by region and gender. The data is presented in a tabular format with columns for Region, Gender, and various metrics.

Region	Gender	Metric 1	Metric 2	Metric 3
North America	Male	15%	25%	35%
	Female	18%	28%	38%
	Male	12%	22%	32%
	Female	14%	24%	34%
Europe	Male	16%	26%	36%
	Female	19%	29%	39%
	Male	13%	23%	33%
	Female	15%	25%	35%
Asia	Male	17%	27%	37%
	Female	20%	30%	40%
	Male	14%	24%	34%
	Female	16%	26%	36%
South America	Male	18%	28%	38%
	Female	21%	31%	41%
	Male	15%	25%	35%
	Female	17%	27%	37%

Objective 3: Supportive Quotes From Discussion (1/7)



Supportive Quotes From Discussion (1/7)	
Topic	Supportive Quotes
Topic 1: [illegible]	[illegible] [illegible] [illegible]
Topic 2: [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible]

Objective 3: Supportive Quotes From Discussion (2/7)



Supportive Quotes From Discussion (2/7)	
Topic	Supportive Quotes
The importance of a supportive environment for learning and development	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”
	“The importance of a supportive environment for learning and development is a key factor in the success of any organization.”

Objective 3: Supportive Quotes From Discussion (3/7)



Supportive Quotes From Discussion (3/7)	
Topic	Supportive Quotes
The importance of having a strong support system when dealing with a chronic illness.	Having a strong support system is crucial when dealing with a chronic illness. It provides emotional support, helps with medication management, and ensures you don't feel alone in your journey.
	When you have a support system, you can share your experiences and feelings with someone who understands. This can be incredibly helpful in managing the emotional aspects of a chronic illness.
	It's important to have someone who can help you with the practical aspects of your illness, such as scheduling appointments, managing medications, and providing transportation to medical visits.
	Supportive friends and family can also help you stay motivated and positive. They can encourage you to stick to your treatment plan and remind you of the progress you've made.
	Having a support system can also help you cope with the stress and anxiety that often accompany a chronic illness. It provides a safe space to express your fears and concerns.
	Overall, a strong support system is essential for managing a chronic illness effectively. It provides the emotional, practical, and motivational support needed to navigate the challenges of a long-term health condition.

Objective 3: Supportive Quotes From Discussion (4/7)

Topic	Key Points
1. Introduction to the course	The course is designed to provide a comprehensive overview of the field of study, covering both theoretical and practical aspects. It is intended for students who are new to the subject and wish to gain a solid foundation in the key concepts and principles. The course is divided into several modules, each focusing on a specific area of the subject. The modules are designed to build on each other, allowing students to develop a deep understanding of the subject matter over the course of the semester. Throughout the course, students will be encouraged to engage in critical thinking and problem-solving exercises, as well as to participate in group discussions and presentations. This approach is intended to foster a collaborative learning environment and to develop the students' ability to apply their knowledge to real-world situations. The course is taught by a team of experienced faculty members who are experts in their respective fields. They will provide guidance and support throughout the course, ensuring that students are able to meet their learning objectives and achieve their full potential.

Objective 3: Supportive Quotes From Discussion (5/7)



Supportive Quotes From Discussion (5/7)	
Topic	Supportive Quotes
Topic 1: [illegible]	[illegible]
	[illegible]
	[illegible]
	[illegible]

Objective 3: Supportive Quotes From Discussion (6/7)



Supportive Quotes From Discussion (6/7)	
Topic	Supportive Quotes
Resilience	Resilience is not a fixed trait, but a skill that can be developed through practice. It is the ability to bounce back from adversity and emerge stronger than before.
	Resilience is not about avoiding stress, but about managing it effectively. It is the ability to stay calm and focused in the face of challenges.
	Resilience is not a solo journey, but a shared one. It is the ability to seek help when needed and offer support to others.
	Resilience is not a destination, but a continuous process. It is the ability to adapt to change and grow from setbacks.
	Resilience is not a luxury, but a necessity. It is the ability to keep going when everything seems to be falling apart.
	Resilience is not a magic pill, but a mindset. It is the ability to see challenges as opportunities for growth.
	Resilience is not a one-time event, but a daily practice. It is the ability to stay positive and hopeful in the face of adversity.
	Resilience is not a guarantee, but a possibility. It is the ability to believe in yourself and your ability to overcome any obstacle.

Objective 3: Supportive Quotes From Discussion (7/7)



Supportive Quotes From Discussion (7/7)	
Topic	Supportive Quotes
Healthcare costs	Healthcare costs are a major concern for many people. The cost of healthcare is rising rapidly, and this is a major concern for many people. The cost of healthcare is rising rapidly, and this is a major concern for many people. Healthcare costs are a major concern for many people. The cost of healthcare is rising rapidly, and this is a major concern for many people. The cost of healthcare is rising rapidly, and this is a major concern for many people.
Healthcare quality	Healthcare quality is a major concern for many people. The quality of healthcare is rising rapidly, and this is a major concern for many people. The quality of healthcare is rising rapidly, and this is a major concern for many people. Healthcare quality is a major concern for many people. The quality of healthcare is rising rapidly, and this is a major concern for many people. The quality of healthcare is rising rapidly, and this is a major concern for many people.

Objective 3: Strategic Recommendations



Strategic Recommendation 1: Enhance the patient experience through digital health solutions.

Implement a digital health strategy that focuses on improving the patient experience through digital health solutions. This includes implementing a patient portal, mobile health applications, and telehealth services. The goal is to provide patients with convenient, accessible, and secure ways to interact with the healthcare system.

Strategic Recommendation 2: Optimize the operational efficiency of the healthcare system.

Implement a digital health strategy that focuses on improving the operational efficiency of the healthcare system. This includes implementing a patient portal, mobile health applications, and telehealth services. The goal is to provide patients with convenient, accessible, and secure ways to interact with the healthcare system.

Strategic Recommendation 3: Enhance the patient experience through digital health solutions.

Implement a digital health strategy that focuses on improving the patient experience through digital health solutions. This includes implementing a patient portal, mobile health applications, and telehealth services. The goal is to provide patients with convenient, accessible, and secure ways to interact with the healthcare system.

Strategic Recommendation 4: Optimize the operational efficiency of the healthcare system.

Implement a digital health strategy that focuses on improving the operational efficiency of the healthcare system. This includes implementing a patient portal, mobile health applications, and telehealth services. The goal is to provide patients with convenient, accessible, and secure ways to interact with the healthcare system.



Attendee Key Takeaways

Attendee Key Takeaways (1/4)



		1. [Illegible text]
		2. [Illegible text]
		3. [Illegible text]
		4. [Illegible text]
		5. [Illegible text]
		6. [Illegible text]
		7. [Illegible text]
		8. [Illegible text]
		9. [Illegible text]
		10. [Illegible text]
		11. [Illegible text]
		12. [Illegible text]
		13. [Illegible text]
		14. [Illegible text]
		15. [Illegible text]
		16. [Illegible text]
		17. [Illegible text]
		18. [Illegible text]
		19. [Illegible text]
		20. [Illegible text]
		21. [Illegible text]
		22. [Illegible text]
		23. [Illegible text]
		24. [Illegible text]
		25. [Illegible text]
		26. [Illegible text]
		27. [Illegible text]
		28. [Illegible text]
		29. [Illegible text]
		30. [Illegible text]
		31. [Illegible text]
		32. [Illegible text]
		33. [Illegible text]
		34. [Illegible text]
		35. [Illegible text]
		36. [Illegible text]
		37. [Illegible text]
		38. [Illegible text]
		39. [Illegible text]
		40. [Illegible text]
		41. [Illegible text]
		42. [Illegible text]
		43. [Illegible text]
		44. [Illegible text]
		45. [Illegible text]
		46. [Illegible text]
		47. [Illegible text]
		48. [Illegible text]
		49. [Illegible text]
		50. [Illegible text]
		51. [Illegible text]
		52. [Illegible text]
		53. [Illegible text]
		54. [Illegible text]
		55. [Illegible text]
		56. [Illegible text]
		57. [Illegible text]
		58. [Illegible text]
		59. [Illegible text]
		60. [Illegible text]
		61. [Illegible text]
		62. [Illegible text]
		63. [Illegible text]
		64. [Illegible text]
		65. [Illegible text]
		66. [Illegible text]
		67. [Illegible text]
		68. [Illegible text]
		69. [Illegible text]
		70. [Illegible text]
		71. [Illegible text]
		72. [Illegible text]
		73. [Illegible text]
		74. [Illegible text]
		75. [Illegible text]
		76. [Illegible text]
		77. [Illegible text]
		78. [Illegible text]
		79. [Illegible text]
		80. [Illegible text]
		81. [Illegible text]
		82. [Illegible text]
		83. [Illegible text]
		84. [Illegible text]
		85. [Illegible text]
		86. [Illegible text]
		87. [Illegible text]
		88. [Illegible text]
		89. [Illegible text]
		90. [Illegible text]
		91. [Illegible text]
		92. [Illegible text]
		93. [Illegible text]
		94. [Illegible text]
		95. [Illegible text]
		96. [Illegible text]
		97. [Illegible text]
		98. [Illegible text]
		99. [Illegible text]
		100. [Illegible text]

Attendee Key Takeaways (2/4)

- 1. **Univariate** - one variable
- 2. **Bivariate** - two variables
- 3. **Multivariate** - three or more variables

4. **Regression** - a statistical method for estimating the relationship between a dependent variable and one or more independent variables

- 1. **Linear** - the relationship is a straight line
- 2. **Non-linear** - the relationship is not a straight line
- 3. **Logistic** - the dependent variable is categorical

5. **Time series** - data collected over time

- 1. **Autoregressive** - the value of the variable at time t is a function of its value at time $t-1$
- 2. **Moving average** - the value of the variable at time t is the average of its values at times $t-1$, $t-2$, and $t-3$
- 3. **Seasonal** - the value of the variable at time t is a function of the time of day, month, or year

Attendee Key Takeaways (3/4)

- 1. **Ordinary least squares (OLS)** – estimator for regression setting with normally distributed errors
- 2. **Maximum likelihood (ML)** – estimator for regression setting with normally distributed errors
- 3. **Generalized method of moments (GMM)** – estimator for regression setting with normally distributed errors

4. **Bayesian methods** – estimator for regression setting with normally distributed errors, using prior information

- 1. **Bayesian linear regression** – estimator for regression setting with normally distributed errors, using prior information
- 2. **Bayesian logistic regression** – estimator for regression setting with normally distributed errors, using prior information
- 3. **Bayesian probit regression** – estimator for regression setting with normally distributed errors, using prior information

5. **Robust methods** – estimator for regression setting with normally distributed errors, using prior information

- 1. **Robust linear regression** – estimator for regression setting with normally distributed errors, using prior information
- 2. **Robust logistic regression** – estimator for regression setting with normally distributed errors, using prior information
- 3. **Robust probit regression** – estimator for regression setting with normally distributed errors, using prior information

6. **Nonlinear methods** – estimator for regression setting with normally distributed errors, using prior information

- 1. **Nonlinear least squares (NLS)** – estimator for regression setting with normally distributed errors, using prior information
- 2. **Nonlinear maximum likelihood (NML)** – estimator for regression setting with normally distributed errors, using prior information
- 3. **Nonlinear generalized method of moments (NGLS)** – estimator for regression setting with normally distributed errors, using prior information

7. **Machine learning methods** – estimator for regression setting with normally distributed errors, using prior information

- 1. **Support vector machines (SVM)** – estimator for regression setting with normally distributed errors, using prior information
- 2. **Random forests** – estimator for regression setting with normally distributed errors, using prior information
- 3. **Gradient boosting machines (GBM)** – estimator for regression setting with normally distributed errors, using prior information

8. **Deep learning methods** – estimator for regression setting with normally distributed errors, using prior information

- 1. **Deep neural networks (DNN)** – estimator for regression setting with normally distributed errors, using prior information
- 2. **Convolutional neural networks (CNN)** – estimator for regression setting with normally distributed errors, using prior information
- 3. **Recurrent neural networks (RNN)** – estimator for regression setting with normally distributed errors, using prior information

Attendee Key Takeaways (4/4)



- 1. The primary objective is to support the patient in achieving their desired outcome of maintaining their weight.
 - 2. The patient is currently unable to maintain their weight and is at risk of losing weight.
 - 3. The patient's weight loss is a significant concern and is affecting their ability to maintain their weight.
-
- 1. The patient is currently unable to maintain their weight and is at risk of losing weight.
 - 2. The patient's weight loss is a significant concern and is affecting their ability to maintain their weight.
 - 3. The patient's weight loss is a significant concern and is affecting their ability to maintain their weight.



ARS Data

First-Line Therapy of Advanced RCC

Over the Past Year, 60% of Physicians Did Not Treat Any Patients With First-Line Axitinib + Pembrolizumab; 40% Treated 1–3 Patients With This Regimen




Half of Physicians Did Not Use Cabozantinib + Nivolumab as First-Line Therapy in the Past Year; 40% Treated 1–3 Patients With This Regimen




In the Past Year, 40% of Physicians Used First-Line Lenvatinib + Pembrolizumab in 1–3 Patients, 20% Used It in 4–7 Patients, and 30% Reported No Use



Most Physicians (80%) Treated 1–3 Patients With First-Line Ipilimumab + Nivolumab in the Past Year




Among Their Patients Treated With First-Line Ipilimumab + Nivolumab in the Past Year, 60% of Physicians Reported That No Patients Had Favorable-Risk Disease



Overall Survival Most Significantly Influences First-Line Therapy Selection for RCC




Patient Case 1



A 55-year-old male, diagnosed with HIV, is a patient who
presented with a respiratory infection with no obvious
symptoms at the time. The presentation with multiple lung
infiltrates found on CT scan upon evaluation for a cough. The
test was positive for HIV, and normal laboratory tests.


An Equal Proportion of Physicians Selected Cabozantinib + Nivolumab, Ipilimumab + Nivolumab, and Lenvatinib + Pembrolizumab for This Favorable-Risk Patient (30% each)






A 45-year-old woman was initially found to have a brain mass in the left frontal lobe with surrounding vasogenic edema. The mass was approximately 4 cm in diameter. She had no neurological deficits. The mass was resected and the patient was discharged on anti-seizure medication. The mass was found to be a low-grade glioma. The patient is currently on anti-seizure medication and is doing well. The mass was found to be a low-grade glioma. The patient is currently on anti-seizure medication and is doing well.

For This Patient With Multisite Metastases, Half of Physicians Would Recommend Lenvatinib + Pembrolizumab; 30% Prefer Cabozantinib + Nivolumab






Following the surgery, the patient was able to return to her normal activities. She was able to walk independently and was able to perform all activities of daily living. She was able to return to work and was able to resume her normal diet. She was able to return to her normal activities of daily living and was able to perform all activities of daily living. She was able to return to her normal diet and was able to resume her normal activities of daily living.


After Progression on Adjuvant Pembrolizumab, 80% of Physicians Would Recommend Cabozantinib Monotherapy for This Patient; 10% Would Choose Cabozantinib + Nivolumab






A 78-year-old woman presents with several lumps, most in the neck, and pain in the lower right side. CT scan shows a mass in the right neck, consistent with a thyroid gland, and a thyroid nodule. The underlying cause is unknown. Pathology indicates that the nodule is benign. Biopsy of the thyroid nodule confirms that it is benign. Age is 78, weight 150 lb, and 150 cm tall.

For This Patient With Multiorgan Metastases, 44% of Physicians Would Recommend Lenvatinib + Pembrolizumab; 22% Preferred Cabozantinib + Nivolumab, and 11% Opted for Cabozantinib Monotherapy





A 55-year-old male is referred to clinic with a 7-year right-sided hearing loss and no evidence of conductive hearing loss. The audiogram is right-sided sensorineural, and pathology reveals a T-cell clone (CD 45) with immunoglobulin heavy chain and some cells positive, consistent with a T-cell lymphoma. The treatment regimen (interferon- α for 12 months, followed by rituximab) shows disease recurrence with residual very dense 12 months after completion of adjuvant chemotherapy.

Nearly Two-Thirds of Physicians (64%) Would Recommend Ipilimumab + Nivolumab for This Patient With Recurrent Disease After Adjuvant Pembrolizumab







ARS Data


Subsequent Management of Advanced RCC

Most Physicians (78%) Use Cabozantinib Monotherapy in the Second Line After IO + TKI Therapy




Most Physicians (73%) Prescribe Cabozantinib Monotherapy in the Second Line After IO + IO Therapy





The 55-year-old woman with long, wavy, blonde hair and light-colored eyes was seen in the clinic for a follow-up visit. She reported that her symptoms had improved significantly since her last visit. She mentioned that she had been able to return to her normal diet and had not experienced any further episodes of dizziness or lightheadedness. She also noted that her energy levels had improved and that she was feeling more comfortable in her daily activities. The physician reviewed her medical history and current medications, and noted that her blood pressure and heart rate were within normal ranges. The physician recommended that she continue with her current treatment plan and schedule a follow-up visit in four weeks to monitor her progress.


Most Physicians (64%) Preferred Cabozantinib Monotherapy for This Patient With Brain and Osseous Metastases Following Axitinib + Pembrolizumab





A 55-year-old male with long-standing hypertension and chronic kidney disease (CKD) stage 3, who recently started on apixiban + losartan and had evidence of disease progression after 12 months. He then received apixiban + losartan in combination therapy, which was poorly tolerated with rapid loss of appetite and GI toxicity. Managing ongoing renal disease progression. His clinical performance after 12 months was stable, and he had no disease-related symptoms.


64% of Physicians Would Recommend Belzutifan for This Patient With Progression After Prior IO + IO and Lenvatinib + Everolimus Therapy, 18% Chose Tivozanib, and 9% Opted for Cabozantinib



Patient Case 6

A 55-year-old man with history of metastatic clear cell RCC done two and a half cycles received first-line pembrolizumab + apixiban with evidence of disease progression after 15 months of therapy. He then received cabozantinib as second-line therapy and had evidence of disease progression after 12 months, with new and progressive bone and liver lesions. His ECOG performance status is 1, and his disease is symptomatic.

Over Half of Physicians (55%) Would Recommend Belzutifan for This Symptomatic Patient With Progression on First-Line Axitinib + Pembrolizumab and Second-Line Cabozantinib; 27% Chose Tivozanib





US 5901-B Peachtree Dunwoody Road
Suite 415, Atlanta, GA 30328, US

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com

